(311) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR+/HER2– advanced breast cancer: Characterization and management of frequent adverse events from the Phase 3 CAPItello-291 trial
Medical Science Liaison AstraZeneca Mesquite, Texas, United States
To provide a detailed understanding of the safety profile of capivasertib + fulvestrant from the CAPItello-291 study, with a focus on frequent clinically relevant AEs